Israel - Hebrew - Ministry of Health

zoetis israel holding b.v., israel - selamectin - תמיסה - selamectin 120 mg/ml

Israel - Hebrew - Ministry of Health

teva israel ltd - betamethasone as dipropionate; calcipotriol - משחה - calcipotriol 50 mcg / 1 g; betamethasone as dipropionate 0.5 mg / 1 g - calcipotriol, combinations

Israel - Hebrew - Ministry of Health

vetmarket ltd, israel - betamethasone as valerate; fusidic acid as hemihydrate - ג'ל - betamethasone as valerate 0.1 %; fusidic acid as hemihydrate 0.5 %

Israel - Hebrew - Ministry of Health

bayer israel ltd - drospirenone; ethinylestradiol as betadex clathrate; levomefolate calcium; levomefolate calcium - טבליות מצופות פילם - levomefolate calcium 0.451 mg; ethinylestradiol as betadex clathrate 0.02 mg; drospirenone 3 mg; levomefolate calcium 0.451 mg - estradiol, combinations

Israel - Hebrew - Ministry of Health

unipharm ltd, israel - losartan potassium - טבליה - losartan potassium 100 mg - losartan

Israel - Hebrew - Ministry of Health

unipharm ltd, israel - losartan potassium - טבליה - losartan potassium 12.5 mg - losartan

Israel - Hebrew - Ministry of Health

unipharm ltd, israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan

Israel - Hebrew - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta 2000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

Israel - Hebrew - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta 3000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

Israel - Hebrew - Ministry of Health

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta 30 mcg/ml / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic kidney disease (ckd).